Table 1.
Prevalence trends in bacterial vaginosis (BV) diagnosis over seven visits among those with Nugent results at each visit in a cohort of 1027 women at high risk in Kampala, Uganda (2008–2011)
| Enrolment | 3 months | 6 months | 9 months | 12 months | 18 months | 24 months | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| n=1027 | n=886 | n=792 | n=777 | n=759 | n=743 | n=584 | ORtrend* | p Value† | Trend | |
| Normal | 354 (35%) | 330 (37%) | 308 (39%) | 298 (36%) | 301 (40%) | 262 (35%) | 202 (35%) | 1.00 (0.97 to 1.04) | 0.87 | ↔ |
| Intermediate | 100 (10%) | 73 (8%) | 60 (8%) | 49 (6%) | 29 (4%) | 27 (4%) | 14 (2%) | 0.79 (0.74 to 0.84) | <0.001 | ↓ |
| BV | 573 (56%) | 483 (55%) | 424 (54%) | 450 (58%) | 429 (57%) | 454 (61%) | 368 (63%) | 1.07 (1.04 to 1.11) | <0.001 | ↑ |
| BV treated with metronidazole‡ | 400 (70%) | 270 (56%) | 177 (42%) | 138 (31%) | 103 (24%) | 41 (9%) | 22 (6%) | 0.78 (0.75 to 0.82) | <0.001 | ↓ |
| BV with any genital symptoms§ | 402 (70%) | 309 (64%) | 243 (57%) | 244 (54%) | 227 (53%) | 259 (48%) | 159 (43%) | 0.48 (0.45 to 0.52) | <0.001 | ↓ |
*OR for trend in BV prevalence from one 3-monthly follow-up visit to the next.
†Likelihood ratio (LR) test p values were used to examine whether the ORtrend were likely to be due to chance.
‡This is a subset of the BV cases; treatment includes any participants with the diagnosis of BV and who were treated with 2 g of metronidazole in a single dose or 400 mg of metronidazole twice daily for 14 days at that visit.
§This is a subset of the BV cases; ‘any genital symptoms’ included dysuria, genital itching or burning, dyspareunia, lower abdominal pain, abnormal discharge or ulcers/blisters. Genital itching or burning, dysuria and ulcers/blisters are not treated with metronidazole in the syndromic management algorithm.